AxoGen (NASDAQ:AXGN - Get Free Report) is expected to be releasing its earnings data before the market opens on Tuesday, February 25th. Analysts expect AxoGen to post earnings of $0.04 per share and revenue of $49.40 million for the quarter. Parties that are interested in registering for the company's conference call can do so using this link.
AxoGen Stock Performance
Shares of AXGN stock traded up $0.01 on Monday, hitting $18.01. The company's stock had a trading volume of 1,130,028 shares, compared to its average volume of 487,212. AxoGen has a fifty-two week low of $5.55 and a fifty-two week high of $19.19. The company has a market capitalization of $792.58 million, a PE ratio of -56.28 and a beta of 1.00. The stock's 50 day moving average is $17.36 and its 200-day moving average is $14.87. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.47 and a current ratio of 3.74.
Wall Street Analyst Weigh In
Separately, Canaccord Genuity Group raised their target price on shares of AxoGen from $18.00 to $22.00 and gave the stock a "buy" rating in a report on Monday, February 3rd.
Get Our Latest Stock Analysis on AXGN
About AxoGen
(
Get Free Report)
AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.
Further Reading
Before you consider AxoGen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AxoGen wasn't on the list.
While AxoGen currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
